Headquartered in Exton, PA Fiscal year ends December NYSE: WST westpharma.com
West Pharmaceutical Services, Inc. is a provider of injectable solutions and services for the pharmaceutical, biotechnology, and generic drug industries. The company designs, manufactures, and sells containment and delivery systems for injectable drugs, including elastomeric components (stoppers, plungers, seals), prefillable syringe components, and self-injection delivery devices. West operates through two segments: Proprietary Products, which includes High Value Product (HVP) Components, HVP Delivery Devices (such as SmartDose and Crystal Zenith systems), and Standard Products; and West Vantage, which provides contract manufacturing and related services. The company serves three primary market groups — Biologics, Pharma, and Generics — with Biologics representing the largest and fastest-growing portion of revenue at 43% of total sales. West operates over 50 sites including 26 manufacturing facilities worldwide, delivering over 41 billion components and devices annually. Key growth drivers include the expanding biologics market, GLP-1 drug delivery components, and regulatory-driven quality upgrades (Annex 1). The company trades on the NYSE under the ticker WST and is an S&P 500 constituent. Updated
Pre-Market Stock Futures: Futures are trading higher after the bulls tried to rally stocks on Monday, after the drubbing they took on Friday, and it looks the same way today. While it…
West Pharmaceutical Services (NYSE: WST | WST Price Prediction) has ripped 24.2% in the past month and 8.7% in the past week, and the move has the fingerprints of a sustained re-rating.…
Trey Thoelcke West Pharmaceutical Services just sent investors $0.22 per share on February 4, 2026, marking the company’s latest quarterly dividend payment. For a business that’s quietly grown its payout for over a decade,…
Joel South Dividend growth investing focuses on acquiring stocks that consistently increase their dividends, providing investors with a reliable, inflation-beating income stream and potential capital appreciation. This strategy prioritizes companies with strong fundamentals, stable…
The stock market has been on a winning streak as fears about tariffs start cooling. Earnings season has also been solid, and most tech companies have trounced estimates so far. As such,…
Tuesday's top analyst upgrades and downgrades included Activision Blizzard, Adobe, Advanced Micro Devices, Ares Capital, Intel, Lennar, Marvell Technology, NexTier Oilfield Solutions, Nike, Nvidia, SoFi Technologies, Truist Financial, Tyson Foods and ZScaler.
Wednesday's top analyst upgrades and downgrades included Antero Resources, Array Technologies, Bumble, Chewy, EQT, LendingClub, Match, MGIC Investment, Nasdaq, New York Community Bancorp, Palo Alto Networks, Radian, Range Resources, Spotify Technology and Welltower.
The big U.S. indexes traded lower in Friday's premarket, continuing the prior day's trend, and short-term bonds seem to be the place to be.
Monday's top analyst upgrades and downgrades included Altria, Amazon.com, Apple, Axalta Coating Systems, Comcast, Etsy, Intel, McDonald's and Medical Properties Trust.
The S&P 500 index is up about 2% this year, after a spring collapse and remarkable rebound. Among the companies in the index, 10 are up more than 50%.
Thursday's top analyst upgrades, downgrades and initiations included Autodesk, Bausch Health, Charles Schwab, Darden Restaurants, Garmin, GE, Home Depot, Kroger, Merit Medical and Starbucks.
Analysts at Jefferies recently reviewed several pharmaceutical services company stocks and put a Buy rating on four outstanding performers.
Lee Jackson These stocks offer investors strength in their specific industries and the ability to avoid high-flying disasters. All of them are suitable for growth accounts with some degree of risk tolerance.
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, Bristol-Myers, Eli Lilly, First Solar, Generac, Oracle, Sirius XM, Southwest and Wendy's.
Over the past five, 10 and 20 years, the life science and bioproduction segments have tended to outperform the S&P 500 more often than not.
West Pharmaceutical Services, Inc. is a provider of injectable solutions and services for the pharmaceutical, biotechnology, and generic drug industries.
24/7 Wall St.'s 12-month price target for WST is $466.06, rated Buy. The Wall Street consensus target is $411.00. WST price prediction →
